Article
Oncology
Khalid W. Kalim, Jun-Qi Yang, Mark Wunderlich, Vishnu Modur, Phuong Nguyen, Yuan Li, Ting Wen, Ashley Kuenzi Davis, Ravinder Verma, Qing Richard Lu, Anil G. Jegga, Yi Zheng, Fukun Guo
Summary: Targeting Cdc42 in Treg cells has shown promising therapeutic potential in cancer immunotherapy, by enhancing antitumor T-cell immunity without triggering autoimmune reactions. This approach involves inducing Treg cell instability through Cdc42 targeting, leading to improved immune responses against tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Huanhe Ni, Huanling Zhang, Lin Li, He Huang, Hui Guo, Lin Zhang, Chunwei Li, Jing-Xiao Xu, Cai-Ping Nie, Kui Li, Xiaoshi Zhang, Xiaojun Xia, Jiang Li
Summary: In this study, it was found that increased STING and CCL22 levels, as well as higher levels of FOXP3(+) cells and lower levels of CD8(+) cells in tumor tissues of cervical cancer, predicted poor survival. Activation of STING signaling in cooperation with T cell receptor and other signals promoted iTreg differentiation in both human and murine CD4(+) naive T cells. Additionally, tumor-derived exosomes were found to activate STING signaling in tumor-infiltrated T cells, leading to iTreg expansion.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Rui Zhang, Jinlin Miao, Ping Zhu
Summary: Regulatory T (Treg) cells are crucial in maintaining immune homeostasis and are involved in various diseases, particularly autoimmune diseases. Understanding the heterogeneity of Treg cells can provide new insights for selective therapeutic manipulation and treatment of these diseases.
AUTOIMMUNITY REVIEWS
(2021)
Article
Oncology
Tsung-Yi Lin, Jeong A. Park, Alan Long, Hong-Fen Guo, Nai-Kong Cheung
Summary: The study developed a T cell-engaging bispecific antibody named BC261, which demonstrated potent cytotoxicity against EFT, prostate cancer, and canine osteosarcoma cell lines and showed superior antitumor effects in vivo. BC261 not only promoted T cell infiltration into tumors but also exhibited significant antitumor efficacy against various cancer types.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Maximilian O. Schaettler, Rupen Desai, Anthony Z. Wang, Alexandra J. Livingstone, Dale K. Kobayashi, Andrew T. Coxon, Jay A. Bowman-Kirigin, Connor J. Liu, Mao Li, Diane E. Bender, Michael J. White, David M. Kranz, Tanner M. Johanns, Gavin P. Dunn
Summary: Researchers isolated a TCR specific for the Imp3(D81N) neoantigen and generated the MISTIC mouse model. Adoptive cellular therapy using MISTIC T cells showed potential therapeutic efficacy for glioblastoma treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Rasmus Erik Johansson Mortensen, Morten Orebo Holmstrom, Thomas Landkildehus Lisle, Jane P. Hasselby, Gro L. Willemoe, Ozcan Met, Inge Marie Svane, Julia Johansen, Dorte L. Nielsen, Inna M. Chen, Mads Hald Andersen
Summary: This study investigated the significance of TGF-beta-specific T-cell immunity in patients with pancreatic cancer treated with ICI combined with radiotherapy. The results showed that patients with a strong TGF-beta-specific immune response had longer progression-free and overall survival compared to those with a weak or no response. It was also found that TGF-beta-specific T cells could recognize and enhance immune responses. Thus, combining TGF-beta vaccination with ICI/radiotherapy may benefit patients with pancreatic cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jacob Gadwa, Thomas E. Bickett, Laurel B. Darragh, Michael William Knitz, Shilpa Bhatia, Miles Piper, Benjamin Van Court, Shiv Bhuvane, Diemmy Nguyen, Varuna Nangia, Emily K. Kleczko, Raphael A. Nemenoff, Sana D. Karam
Summary: Inhibition of complement C3a and C5a signaling in HNSCC accelerates tumor growth and increases regulatory T cell populations. Local C3a and C5a signaling is important for CD4 T cell homeostasis and development into effector phenotypes. Depletion of Tregs reverses tumor growth and combining Treg depletion with C3a and C5a receptor inhibition reduces tumor growth further.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Sabaria Shah, Katherine W. Cook, Peter Symonds, Juliane Weisser, Anne Skinner, Abdullah Al Omari, Samantha J. Paston, Ian Pike, Lindy G. Durrant, Victoria A. Brentville
Summary: This study discovers that homocitrullinated peptides can be processed and presented via MHC-I for tumor therapy. The modified peptides show enhanced binding to HLA-A2 and induce high avidity homocitrulline-specific CD8 T-cell responses, which can kill target cells expressing the peptide.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Audrey Moatti, Anais Debesset, Caroline Pilon, Asma Beldi-Ferchiou, Mathieu Leclerc, Rabah Redjoul, Frederic Charlotte, Nhu Hanh To, Adeline Bak, Yazid Belkacemi, Benoit Laurent Salomon, Fadi Issa, David Michonneau, Sebastien Maury, Jose Laurent Cohen, Allan Thiolat
Summary: This study reveals the potential of targeting TNFR2 to enhance anti-tumor responses and treat relapse of blood malignancies. The researchers also found that TNFR2 is over-expressed in Tregs from healthy donors and patients with leukemia relapse or GVHD. These findings provide new perspectives for the development of immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
MacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake Ceccarelli, T. J. Langer, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, Daniel Abate-Daga, James J. Mule, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Summary: This study highlights the importance of neoantigen-specific CD4(+)T cells within tumor-infiltrating lymphocytes (TILs) as a potent source of tumor-specific effectors. The findings suggest that these CD4(+)T cells play a significant role in antitumor immunity and should be included in future adoptive cell therapy (ACT) protocols to improve treatment efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jitske van den Bulk, Manon van der Ploeg, Marieke E. Ijsselsteijn, Dina Ruano, Ruud van der Breggen, Rebekka Duhen, Koen C. M. J. Peeters, Arantza Farina-Sarasqueta, Els M. E. Verdegaal, Sjoerd H. van der Burg, Thomas Duhen, Noel F. C. C. de Miranda
Summary: Expression of CD103 and CD39 can specifically identify neoantigen-specific CD8(+) T cells in colorectal cancers (CRCs) with low mutation burden.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Concetta Ragone, Carmen Manolio, Beatrice Cavalluzzo, Angela Mauriello, Maria Lina Tornesello, Franco M. Buonaguro, Filippo Castiglione, Luigi Vitagliano, Emanuela Iaccarino, Menotti Ruvo, Maria Tagliamonte, Luigi Buonaguro
Summary: This study identifies homology between viral antigens and tumor antigens, suggesting potential cross-reactive immune responses. The research indicates that antiviral T cell memory may play a significant role in combating cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Anna Luise Bernhardt, Julia Zeun, Miriam Marecek, Hannah Reimann, Sascha Kretschmann, Judith Bausenwein, Edith D. van der Meijden, Margarete M. Karg, Tabea Haug, Lisa Meintker, Gloria Lutzny-Geier, Andreas Mackensen, Anita N. Kremer
Summary: The study successfully generated DM-sensitive and DM-resistant variants for two model antigens, demonstrating that DM-sensitive antigens are not inferior to their DM-resistant counterparts in terms of immunogenicity, and can potentially serve as interesting tools for immunotherapy after allogeneic stem cell transplantation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Mengmeng Jiang, Yang Yang, Liling Niu, Ping Li, Yibo Chen, Ping Liao, Yifei Wang, Jingbin Zheng, Fengyang Chen, Huanhuan He, Hui Li, Xin Chen
Summary: miR-125b-5p regulates Tregs function and TNFR2 expression, enhancing antitumor efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Evripidis Lanitis, Paris Kosti, Catherine Ronet, Elisabetta Cribioli, Giorgia Rota, Aodrenn Spill, Patrick Reichenbach, Vincent Zoete, Denarda Dangaj Laniti, George Coukos, Melita Irving
Summary: CAR-T cells have shown potent immunotherapy against hematological malignancies, but face challenges in treating solid tumors due to lack of broadly expressed antigens and suppressive mechanisms in the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)